Table 1

Summary of cases

Report	Age/sex	Symptoms	Months after second alemtuzumab dose	APTT (s)	FVIII activity	FVIII inhibitor activity (BU/mL)	Treatment to control bleeding	Treatment to eliminate the inhibitor
Pisa et al5	46/F	Abnormal bruising after minimal trauma: left palm, top of foot, right hand, popliteus haematoma	7	Ratio 2.95*	1%	128	Recombinant FVIIa	Prednisolone 75 mg and cyclophosphamide 100 mg; following relapse, switched to methylprednisolone and azathioprine
McCaughan et al3	37/F	Progressive right leg pain, swelling, bruising; left arm and thigh non-purpuric masses	9	71 (n 24–38)	2 U/dL	5.7	Recombinant FVIIa	Prednisolone 1 mg/kg
Madeley et al4	36/M	Easy bruising and epistaxis, then left thigh haematoma	48	88	<0.01 U/dL	7	Recombinant FVIIa	Prednisolone 1 mg/kg and rituximab
Brink et al6	42/M	Extensive gluteal haematoma	12	87	<0.1%	45	Factor VIII bypassing fraction	Prednisolone and cyclophosphamide
Gounder et al (current report)	48/F	Spontaneous bruising over arms and flanks	21	85 (n 25–35)	<0.02 U/dL	51.2	Not required	Prednisolone 75 mg and cyclophosphamide 50 mg
Gounder et al (current report)	31/F	Menorrhagia and easy bruising	21	48 (n 22–35)	0.22 U/dL	1	Tranexamic acid	Prednisolone 50 mg and cyclophosphamide 50 mg

APTT, activated partial thromboplastin time; F, female; FVIII, factor VIII; M, male.